PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...

PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...

Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development ...

Under no circumstances this document is to be used or considered as an offer to sell, or a solicitation of any offer to buy, any security. While information contained herein has been obtained from ...

28 Aug 2014 31 Oct 2014 14 Nov 2014 3rd Interim Single Tier 9.5sen 29 Oct 2014 20 Aug 2015 07 Oct 2015 23 Oct 2015 Interim Single Tier 9.5sen 05 Oct 2015 25 Aug 2016 31 Oct 2016 15 Nov 2016 ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.